Evidence map›Paper›PMID 30167992›Full record

ArticleDrug safety2018

Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab.

Karen Smith, Su Golder, Abeed Sarker, Yoon Loke, Karen O'Connor, Graciela Gonzalez-Hernandez

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Drug safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Pharmacovigilance in the digital age: gaining insight from social media data.Experimental biology and medicine (Maywood, N.J.) · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Self-reported adverse events associated with ∆Journal of cannabis research · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Leveraging digital media data for pharmacovigilance.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Karen SmithRueckert-Hartman College for Health Professions, Regis University, Denver, CO, USA.
Su GolderDepartment of Health Sciences, University of York, York, UK.
Abeed SarkerDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-7358-544X
Yoon LokeNorwich Medical School, University of East Anglia, Norwich, UK.
Karen O'ConnorDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Graciela Gonzalez-HernandezDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. gragon@pennmedicine.upenn.edu.
University of Pennsylvania · USRegis University · USUniversity of East Anglia · GBUniversity of York · GB

Funding

Social Media Mining for PharmacovigilanceR01LM011176 · NLM · UNIVERSITY OF PENNSYLVANIA · PI GONZALEZ HERNANDEZ, GRACIELA, SHEN, LI · 2012 to 2021
$4.5M
Department of Health PDF-2014-07-041NLM NIH HHS R01 LM011176
6 · The paper itself

Abstract

introductionAdverse drug reactions (ADRs) are associated with significant health-related and financial burden, and multiple sources are currently utilized to actively discover them. Social media has been proposed as a potential resource for monitoring ADRs, but drug-specific analytical studies comparing social media with other sources are scarce.

objectivesOur objective was to develop methods to compare ADRs mentioned in social media with those in traditional sources: the US FDA Adverse Event Reporting System (FAERS), drug information databases (DIDs), and systematic reviews.

methodsA total of 10,188 tweets mentioning adalimumab collected between June 2014 and August 2016 were included. ADRs in the corpus were extracted semi-automatically and manually mapped to standardized concepts in the Unified Medical Language System. ADRs were grouped into 16 biologic categories for comparisons. Frequencies, relative frequencies, disproportionality analyses, and rank ordering were used as metrics.

resultsThere was moderate agreement between ADRs in social media and traditional sources. "Local and injection site reactions" was the top ADR in Twitter, DIDs, and systematic reviews by frequency, ranked frequency, and index ranking. The next highest ADR in Twitter-fatigue-ranked fifth and seventh in FAERS and DIDs.

conclusionSocial media posts often express mild and symptomatic ADRs, but rates are measured differently in scientific sources. ADRs in FAERS are reported as absolute numbers, in DIDs as percentages, and in systematic reviews as percentages, risk ratios, or other metrics, which makes comparisons challenging; however, overlap is substantial. Social media analysis facilitates open-ended investigation of patient perspectives and may reveal concepts (e.g. anxiety) not available in traditional sources.

Indexed as

Proof of Concept StudyAdalimumabAdverse Drug Reaction Reporting SystemsAnti-Inflammatory AgentsDatabases, PharmaceuticalHumansSocial MediaSystematic Reviews as TopicUnited StatesUnited States Food and Drug AdministrationAdalimumabAnti-Inflammatory Agents

Identifiers

PMID30167992
PMCPMC6223697
OpenAlexW2888918154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.